Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

Current and emerging treatments for vitiligo

Vitiligo: Translational research and effective therapeutic strategies

Emerging drugs for the treatment of vitiligo

Emerging therapies and innovations in vitiligo management: a comprehensive review

Updates and new medical treatments for vitiligo (Review)

Up-and-Coming Drugs for the Treatment of Vitiligo

Vitiligo: advances in pathophysiology research and treatment development

Advances in vitiligo: Update on therapeutic targets

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Vitiligo nonsurgical treatment: a review of latest treatment researches

Management of the refractory vitiligo patient: current therapeutic strategies and future options

Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments

Implication of colloidal therapeutics in the treatment of vitiligo: Portray of signaling cascade, current drug-targets and preclinical and clinical evidences

Understanding Vitiligo: Causes, Diagnosis, Promising Advances in Treatment and Management and the Impact on Mental Health

Vitiligo: From Pathogenesis to Treatment

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

The enigma and challenges of vitiligo pathophysiology and treatment

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations

Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection

Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review